As of 2024-10-08, the Relative Valuation of Rigel Pharmaceuticals Inc (RIGL) is (18.97) USD. This relative valuation is based on P/E multiples. With the latest stock price at 15.39 USD, the upside of Rigel Pharmaceuticals Inc based on Relative Valuation is -223.3%.
The range of the Relative Valuation is (15.79) - (17.44) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.1x - 42.9x | 25.4x |
| Forward P/E multiples | 19.5x - 21.6x | 21.5x |
| Fair Price | (15.79) - (17.44) | (18.97) |
| Upside | -202.6% - -213.3% | -223.3% |
| Date | P/E |
| 2024-10-07 | -19.02 |
| 2024-10-04 | -19.83 |
| 2024-10-03 | -19.84 |
| 2024-10-02 | -20.51 |
| 2024-10-01 | -20.24 |
| 2024-09-30 | -20.00 |
| 2024-09-27 | -20.30 |
| 2024-09-26 | -19.78 |
| 2024-09-25 | -19.84 |
| 2024-09-24 | -20.21 |
| 2024-09-23 | -16.89 |
| 2024-09-20 | -17.01 |
| 2024-09-19 | -16.92 |
| 2024-09-18 | -16.85 |
| 2024-09-17 | -16.91 |
| 2024-09-16 | -17.00 |
| 2024-09-13 | -16.93 |
| 2024-09-12 | -16.01 |
| 2024-09-11 | -16.03 |
| 2024-09-10 | -15.88 |
| 2024-09-09 | -16.61 |
| 2024-09-06 | -16.47 |
| 2024-09-05 | -16.58 |
| 2024-09-04 | -16.29 |
| 2024-09-03 | -16.22 |
| 2024-08-30 | -16.61 |
| 2024-08-29 | -16.75 |
| 2024-08-28 | -15.95 |
| 2024-08-27 | -16.33 |
| 2024-08-26 | -16.63 |
| 2024-08-23 | -15.43 |
| 2024-08-22 | -14.94 |
| 2024-08-21 | -15.48 |
| 2024-08-20 | -15.48 |
| 2024-08-19 | -15.71 |
| 2024-08-16 | -14.97 |
| 2024-08-15 | -15.41 |
| 2024-08-14 | -14.80 |
| 2024-08-13 | -15.66 |
| 2024-08-12 | -13.91 |
| 2024-08-09 | -12.62 |
| 2024-08-08 | -12.89 |
| 2024-08-07 | -12.20 |
| 2024-08-06 | -11.53 |
| 2024-08-05 | -10.88 |
| 2024-08-02 | -11.99 |
| 2024-08-01 | -12.40 |
| 2024-07-31 | -13.08 |
| 2024-07-30 | -13.15 |
| 2024-07-29 | -13.12 |